October 29, 2026- Baxter International Inc. reported results for the third quarter of 2026.
Third-Quarter 2026 Companywide Financial Results
Unless otherwise noted, all financial results reflect continuing operations and exclude Baxter’s former Kidney Care business, which is reported as discontinued operations.
- Worldwide sales in the third quarter totaled approximately $2.98 billion, increasing 5% on both a reported and organic basis.
- U.S. sales in the third quarter totaled approximately $1.6 billion, increasing 3% on a reported basis and 5% on an organic basis.
- International sales in the third quarter totaled approximately $1.4 billion, increasing 7% on a reported basis and 6% on an organic basis.
- On a U.S. GAAP basis, net income totaled $298 million, or $0.57 per diluted share.
- On an adjusted basis, net income in the third quarter was $0.58 per diluted share, decreasing 16% due to a higher effective tax rate, year-over-year.
- Free cash flow was $448 million in the third quarter and totaled $705 million year-to-date.
- During the third quarter, the company completed a $600 million cash tender offer, retiring $864 million of debt and accelerating deleveraging while supporting its investment-grade credit objectives.